Project Grant R01CA296978
Award Date
1/16/25
Completion Date
12/31/29
Dollars Obligated
$703K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $696,569 to New York University School of Medicine to conduct research aimed at developing novel therapies for lung cancer. The key objectives are to: 1) characterize the impact of the protein lipocalin 2 (LCN2) on the tumor microenvironment, 2) develop antibody-based therapeutics that interfere with LCN2 and assess their efficacy as monotherapy and in combination with immune checkpoint...
This is a Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research federal grant program (CFDA 93.395). The project aims to investigate the therapeutic targeting of SMARCA2, a chromatin remodeling subunit, in lung cancers with SMARCA4 deficiency. The $557,418 award will support the development of genetically engineered mouse models to evaluate the impact of SMARCA2 degradation on tumor progression and to elucidate the underlying mechanisms. The research...
This $3,787,956 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by New York University (NYU) School of Medicine to investigate and target replication stress in small cell lung cancer (SCLC). The research aims to 1) understand how the protein SLFN11 informs chemo-responsiveness in SCLC subtypes, 2) study how replication stress response pathways and modulators regulate chemo-sensitivity, and 3) develop strategies to...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to the Sloan-Kettering Institute for Cancer Research to investigate mechanisms through which deficiency of the SMARCA4 gene promotes metastasis in lung adenocarcinoma. The research aims to elucidate the role of the ROR2/p-GSK3bS9 signaling pathway in driving metastasis in SMARCA4-deficient lung cancer. Key activities include conducting RNA-seq, ChIP-seq, ATAC-seq, and mass...
This $730,400 Project Grant award under the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research conducted by the Sloan-Kettering Institute for Cancer Research to investigate the metabolic control of malignant cell states in lung adenocarcinoma (LUAD). The overarching goal is to determine how specific configurations of the tricarboxylic acid (TCA) cycle, a central metabolic pathway, contribute to the emergence and maintenance of LUAD cell states that...
This $631,156 federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research to uncover mechanisms driving lineage plasticity in lung cancer. The award recipient, the Icahn School of Medicine at Mount Sinai, will systematically investigate how genetic and epigenetic changes, particularly in the Notch signaling pathway and lineage-determining transcription factors, contribute to the transition from lung adenocarcinoma to the...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) in the amount of $191,675 is funding research to investigate the role of Jumonji demethylases as druggable targets for treating small cell lung cancer (SCLC), including in SCLC that has developed resistance to standard chemotherapy. The research will explore a three-pronged therapeutic approach: using Jumonji inhibitors as first-line therapy, treating etoposide-resistant SCLC with Jumonji...
This federal Project Grant award, valued at $234,730.00, was provided by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The funding supports research to define the transcriptional and epigenetic signatures in normal lung tissue that predispose to lung cancer development, as well as the molecular phenotypes of resulting lung tumors in a mouse model. The central hypothesis is that preexisting epigenetic perturbations in lung tissue...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,827 to New York University School of Medicine to conduct research aimed at enhancing KRAS inhibitor therapy for cancer treatment. The key objectives are to 1) evaluate four serine/threonine kinase family members as synthetic lethal targets for KRAS G12C inhibitors more broadly and in vivo, and 2) use CRISPR/Cas9 screens to define the synthetic lethality and resistance landscape for...
This $548,915 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to the Fred Hutchinson Cancer Center in Seattle, WA will fund research to interrogate a novel tumor suppression axis in small cell lung cancer (SCLC). The research aims to leverage genetically engineered mouse models and cellular models of SCLC to elucidate the biological roles of the SAPK/AP-1 signaling pathway in SCLC tumor suppression. The project will generate mouse...